Join the 'Xyntha' group to help and get support from people like you.
Posted 31 Jul 2015 by Drugs.com
FRIDAY, July 31, 2015 – Treatment costs for one childhood illness, hemophilia, may use up a big chunk of a state's Medicaid budget, a new study out of California shows. The researchers found that treatments for hemophilia – a rare, inherited disorder in which blood does not clot normally – accounted for the largest share of spending on outpatient drugs among publicly insured children in California with serious chronic illnesses. The study "underscores the potential effect of new, expensive but [effective] pharmaceuticals on public insurance programs for children with chronic illness," wrote a group led by Sonja Swenson of Stanford University. Her team published the findings July 28 in the Journal of the American Medical Association. The researchers tracked 2010-2012 data from more than 34,300 publicly insured children and young adults under the age of 21 in California with serious ... Read more
Related support groups: Hemophilia A, Hemophilia, Antihemophilic Factor, Hemophilia B, ReFacto, Humate-P, Advate, Hyate:C, Xyntha, Genarc, Monoclate, Eloctate, Advate rAHF-PFM, Koate-HP, Helixate, Optivate, Beriate P, Kogenate Bayer, Hemophilia A with Inhibitors, Helixate NexGen